Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
Ontology highlight
ABSTRACT: To evaluate the antitumor activity of SU011248 in advanced, imatinib mesylate-resistant gastrointestinal stromal tumor (GIST) when administered on a continuous daily dosing schedule
DISEASE(S): Imatinib Mesylate-resistant Malignant Gastrointestinal Stromal Tumor,Gastrointestinal Stromal Tumors
PROVIDER: 2014803 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA